Piroximone

Piroximone

SCHEMBL119758

CCc1[nH]c(=O)[nH]c1C(=O)c1ccncc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 4/20 1.00
PDE3A Q14432 4/20 1.00
PDE4A P27815 17/20 0.64
PDE4B Q07343 17/20 0.64
PDE4C Q08493 17/20 0.64
PDE4D Q08499 17/20 0.64
NPSR1 Q6W5P4 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
HPGD P15428 1/20 0.43
ALOX15 P16050 1/20 0.43
TSHR P16473 1/20 0.43
NFKB1 P19838 1/20 0.43
BLM P54132 1/20 0.43
PMP22 Q01453 1/20 0.43
ATM Q13315 1/20 0.43
HSD17B10 Q99714 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10864124 0.85 PDE3B (0.74) PDE3BPDE3APDE4APDE4BPDE4C
SCHEMBL10876599 0.84 PDE3B (0.73) PDE3BPDE3APDE4APDE4BPDE4C
SCHEMBL7446222 0.84 PDE3B (0.72) PDE3BPDE3APDE4APDE4BPDE4C
SCHEMBL10876292 0.84 PDE3B (0.72) PDE3BPDE3APDE4APDE4BPDE4C
SCHEMBL9787143 0.83 PDE3B (0.71) PDE3BPDE3APDE4APDE4BPDE4C
SCHEMBL10632760 0.83 PDE3B (0.70) PDE3BPDE3APDE4APDE4BPDE4C
SCHEMBL7434193 0.82 PDE3B (0.70) PDE3BPDE3APDE4APDE4BPDE4C
SCHEMBL7441027 0.80 PDE3B (0.67) PDE3BPDE3APDE4APDE4BPDE4C
SCHEMBL7430671 0.80 PDE3B (0.67) PDE3BPDE3APDE4APDE4BPDE4C
SCHEMBL10635478 0.79 PDE3B (0.65) PDE3BPDE3APDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023196821-A2 TARGETING NEUROPOD CELL GUCY2C TO CONTROL VISCERAL PAIN AND APPETITE THOMAS JEFFERSON UNIVERSITY (US) 2023-10-12 WO claimed
EP-3621593-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES Cardix Therapeutics LLC (US) 2020-03-18 EP claimed
WO-2019194866-A1 DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES Cardix Therapeutics LLC (US) 2019-10-10 WO claimed
US-20190231786-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES CARDIX Therapeutics, LLC 2019-08-01 US claimed
US-20190070184-A1 DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES Cardix Therapeutics LLC (US) 2019-03-07 US claimed
US-20180325907-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES CARDIX Therapeutics, LLC 2018-11-15 US claimed
WO-2018208723-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES Cardix Therapeutics LLC (US) 2018-11-15 WO claimed
US-10117869-B2 PDE III inhibitors for treatment of asymptomatic heart failure BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2018-11-06 US claimed
EP-3210605-A1 USE OF PDE III INHIBITORS FOR THE TREAMENT OF ASYMPTOMATIC (OCCULT) HEART FAILURE Boehringer Ingelheim Vetmedica GmbH (DE) 2017-08-30 EP claimed
US-9463199-B2 Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2016-10-11 US claimed
WO-2000012076-A1 NITROSATED AND NITROSYLATED PHOSPHODIESTERASE INHIBITORS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2000-03-09 WO claimed
EP-0961616-A1 NON-HORMONAL METHOD OF CONTRACEPTION THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 1999-12-08 EP claimed
WO-1999020223-A2 LUTEINISING HORMONE ANTAGONISTS USEFUL FOR TREATMENT OF ESTROGEN DEFICIENCIES, OR AS A CONTRACEPTIVE NOVO NORDISK A/S (DK) 1999-04-29 WO claimed
WO-1999014239-A1 COMPOSITION FOR TREATING DIABETES MELLITUS AND OBESITY FORSSMANN WOLF GEORG (DE) 1999-03-25 WO claimed
WO-1998010765-A1 NON-HORMONAL METHOD OF CONTRACEPTION THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 1998-03-19 WO claimed
US-4868182-A HYPOTENSIVE AND CARDIOTONIC, SYNERGISTIC MERRELL DOW PHARMACEUTICALS INC. (US) 1989-09-19 US claimed
EP-0268146-A1 Enhancement of prazosin MERRELL DOW PHARMACEUTICALS INC. (US) 1988-05-25 EP claimed
EP-0059948-B1 NOVEL AROYLIMIDAZOLONES MERRELL DOW PHARMACEUTICALS INC. (US) 1985-11-13 EP claimed
US-4405628-A 4-Pyridylimidazolones and method of use MERRELL DOW PHARMACEUTICALS INC. (US) 1983-09-20 US claimed
EP-0059948-A1 Novel aroylimidazolones MERRELL DOW PHARMACEUTICALS INC. (US) 1982-09-15 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190070184-A1 DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES ADRB2, ADRA2C, ADRB1 PDE3B 84/4885PDE3A 81/4885PDE4A 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.